The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

Gynecologic Oncology

Volumn 102, Issue 3, 2006, Pages 425-428

  Numnum, T Michael ^a   Rocconi, Rodney P ^a   Whitworth, Jenny ^a   Barnes, Mack N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bevacizumab; Ovarian carcinoma; Vascular endothelial growth factor; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IRINOTECAN; PACLITAXEL; TOPOTECAN;

ABDOMINAL DISTENSION; ADULT; ANAMNESIS; ANOREXIA; ARTICLE; ASCITES TUMOR; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; HUMAN; NAUSEA; OVARY CARCINOMA; PARACENTESIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; TERMINAL DISEASE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ASCITES; CARCINOMA; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33748475636     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.05.018     Document Type: Article

References (19)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. CA Cancer J Clin 55 1 (2005 (Jan-Feb)) 10-30
2. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10 5 (1992 (May)) 706-717
3. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 1 (1996 (Jan 4)) 1-6
4. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 17 (2003 (Sep 1)) 3194-3200
5. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003 (Jul 31)) 427-434
6. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004 (Jun 3)) 2335-2342
7. Monk B.J., Choi D.C., Pugmire G., and Burger R.A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 96 (2005) 902-905
8. Mesiano S., Ferrara N., and Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153 4 (1998 (Oct)) 1249-1256
9. Gossmann A., Helbich T.H., Mesiano S., Shames D.M., Wendland M.F., Roberts T.P., et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 183 4 (2000 (Oct)) 956-963
10. Hu L., Hofmann J., Zaloudek C., Ferrara N., Hamilton T., and Jaffe R.B. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161 5 (2002 (Nov)) 1917-1924
11. Folkman J. Tumor angiogenesis. Adv Cancer Res 19 (1974) 331-358
12. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 6 (2003 (Jun)) 401-410
13. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996 (Aug 9)) 353-364
14. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 4 (2004 (Aug)) 581-611
15. Fontanini G., Vignati S., Boldrini L., Chine S., Silvestri V., Lucchi M., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3 6 (1997 (Jun)) 861-865
16. Gasparini G., Toi M., Gion M., Verderio P., Dittadi R., Hanatani M., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89 2 (1997 (Jan 15)) 139-147
17. Takahashi Y., Tucker S.L., Kitadai Y., Koura A.N., Bucana C.D., Cleary K.R., et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132 5 (1997 (May)) 541-546
18. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 3 (2005 (Feb 1)) 671-680
19. Burger R.A., Sill M., Monk B.J., Greer B., and Sorosky J. Phase II trial of bevacizumab in persistent or recurrent ovarian carcinoma (EOC) or primary peritoneal carcinoma (PPC): a Gynecologic Oncology Group (GOG) study. Proceedings of the American Society of Clinical Oncology (2005) Abstract No. 5009